Cardiomyopathy Clinical Trials

248 recruitingLast updated: June 17, 2026

There are 248 actively recruiting cardiomyopathy clinical trials across 54 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, Cleveland, Ohio, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Cardiomyopathy Trials at a Glance

248 actively recruiting trials for cardiomyopathy are listed on ClinicalTrialsFinder across 6 cities in 54 countries. The largest study group is Not Applicable with 60 trials, with the heaviest enrollment activity in Boston, Cleveland, and New York. Lead sponsors running cardiomyopathy studies include Bristol-Myers Squibb, China National Center for Cardiovascular Diseases, and Second Affiliated Hospital, School of Medicine, Zhejiang University.

Browse cardiomyopathy trials by phase

Treatments under study

About Cardiomyopathy Clinical Trials

Looking for clinical trials for Cardiomyopathy? There are currently 29 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cardiomyopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cardiomyopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 248 trials

Recruiting

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

ObesityCardiomyopathyLi-Fraumeni Syndrome+3 more
National Heart, Lung, and Blood Institute (NHLBI)5,000 enrolled3 locationsNCT01143454
Recruiting

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb1,700 enrolled99 locationsNCT05489705
Recruiting
Not Applicable

Psychosocial Support for Patients With Takotsubo Syndrome

Takotsubo Cardiomyopathy
Weill Medical College of Cornell University24 enrolled1 locationNCT05977049
Recruiting
Phase 3

LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

Hypertrophic Cardiomyopathy (HCM)
Rennes University Hospital532 enrolled17 locationsNCT07202897
Recruiting
Phase 3

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals1,250 enrolled233 locationsNCT07052903
Recruiting
Phase 4

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

Transthyretin Amyloid Cardiomyopathy
Bayer50 enrolled10 locationsNCT07298044
Recruiting

Clinical Course Of Disease In Participants With FA-CM

CardiomyopathyFriedreich Ataxia
Lexeo Therapeutics65 enrolled19 locationsNCT06865482
Recruiting

EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases

PericarditisRheumatoid ArthritisSarcoidosis+10 more
Assistance Publique - Hôpitaux de Paris5,000 enrolled1 locationNCT07077304
Recruiting

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Cardiac AmyloidosisCardiomyopathy, HypertrophicLumbar Spinal Stenosis+3 more
Columbia University1,663 enrolled6 locationsNCT06034405
Recruiting
Phase 2Phase 3

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Symptomatic Genetic Dilated Cardiomyopathy
Kardigan, Inc.332 enrolled43 locationsNCT07210723
Recruiting

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

Heart FailureCardiotoxicityMyocardial Infarction+12 more
Peerbridge Health, Inc2,000 enrolled8 locationsNCT06699056
Recruiting
Phase 4

Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

Heart FailureHeart Failure Due to Coronary Artery DiseaseValvular Cardiomyopathy
Kyungsub Song80 enrolled4 locationsNCT07572032
Recruiting

Multimodal mAgnetic Resonance imaGIng in Cardiovascular Disease

CardiomyopathyCardiovascular DiseasesHeart Valve Diseases+2 more
Second Affiliated Hospital, School of Medicine, Zhejiang University2,000 enrolled1 locationNCT07617844
Recruiting
Phase 3

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled290 locationsNCT07207811
Recruiting
Not Applicable

High Fat Diet for Cardiac Metabolic Reprogramming

Heart Failure With Reduced Ejection FractionNon-ischemic Dilated Cardiomyopathy
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III80 enrolled5 locationsNCT06747429
Recruiting
Not Applicable

Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial

Myocardial ischaemiaHypertrophic Obstructive Cardiomyopathy \(HOCM\)Left Ventricular Outflow Tract Obstruction
University of Manchester75 enrolled1 locationNCT07120776
Recruiting

The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome

Heart FailureMicrovascular DysfunctionTako Tsubo Cardiomyopathy+2 more
University Medical Centre Ljubljana40 enrolled1 locationNCT07604467
Recruiting
Phase 2

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.165 enrolled67 locationsNCT07023614
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

Non-obstructive Hypertrophic CardiomyopathyObstructive Cardiomyopathy, Hypertrophic
Lexicon Pharmaceuticals500 enrolled108 locationsNCT06481891
Recruiting
Phase 4

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy (HCM)
Oregon Health and Science University40 enrolled2 locationsNCT07600177